Pharmaprojects: 医薬品開発パイプラインのデータベース

Find the right investigators and sites for your clinical trial using granular, real-world data.

Gain vital insight into study feasibility, site selection, and investigator prioritization with granular data from the new Informa Pharma Intelligence Patient Proximity API. Protect yourself against costly trial delays by using it to choose the right investigators with relevant and sizable patient proximity. 

Medtech Insight: 世界の医療機器・医療技術の最新情報

Diagnostics Development For Coronavirus Begins As Second US Patient Tests Positive

Bioresearchers at the Centers for Disease Control and Prevention are hoping that diagnostic platforms previously used to develop tests for outbreaks of other epidemic respiratory diseases, including SARS and MERS, can be built on to develop new diagnostics to detect more cases in the current coronavirus outbreak, US infectious disease authorities say. This comes as more patients are monitored around the US for the disease, and a Chicago woman returning from China tests positive.

Medtech Insight: 世界の医療機器・医療技術の最新情報

FDA ‘Stands Ready’ To Fight Coronavirus Via Emergency-Use Test Kits While WHO Mulls Virus Spread, Gets Out Guidance

The US Food and Drug Administration (FDA) stands poised to proceed with hastened approvals for 2019-coronavirus (nCoV) diagnostics, treatments and vaccines, if a public health emergency is declared, after an infected US traveler who caught the disease in Wuhan, China returned from the province to Washington State. Spread of the disease has reached a crisis level in China, and the World Health Organization met on 22 and 23 January to consider what actions to take to contain the virus, while issuing an interim laboratory test guidance for use in diagnosing the disease.

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Datamonitor Healthcare's Top Research Reports

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law

After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.

Breast Cancer Clinical Landscape and Recent Trends Whitepaper

Get a deeper understanding of breast cancer clinical trials initiated since 2014 and what the trends have meant for strategies in this area, with this free whitepaper from Citeline.

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

US FDA Approval Of Lynparza For Pancreatic Cancer Opens Door For PFS Endpoint In Disease

AstraZeneca's PARP inhibitor Lynparza becomes first US FDA-approved drug for pancreatic cancer based on progression-free survival endpoint, providing regulatory precedent for other sponsors to use that development approach; all other pancreatic cancer drugs had been approved based on an overall survival benefit.

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Alnylam Seeking Lumasiran Approvals Soon, But Has Two Rivals On Its Heels

Phase III results support early 2020 filings for what could be the RNAi specialist’s third commercial product, but two competing drugs for primary hyperoxaluria from Dicerna and OxThera aren’t far behind.